跳至主要内容
临床试验/NCT01426997
NCT01426997已完成不适用

Phenotyping Major Depression With Increased Inflammation

Emory University1 个研究点 分布在 1 个国家目标入组 279 人开始时间: 2010年7月最近更新:
适应症

试验速览

阶段
不适用
状态
已完成
入组人数
279
试验地点
1
主要终点
We are using clinician administered and self report psychiatric measurements to compare relevant symptom domains in patients with major depression and increased inflammation versus patients with major depression without increased inflammation.

研究概览

简要总结

To facilitate the development of a personalized approach to the treatment of patients with major depression, this study is designed to elaborate the clinical and neurobiological phenotype of depressed patients with increased inflammation. The data obtained in this proposal will allow the investigators to test the hypothesis that depression and inflammation interact to elaborate a relatively discreet phenotype that warrants an individualized approach to diagnosis and treatment of patients with depression. Moreover, the identification of specific environmental risk factors for inflammation will foster the elaboration of preventative strategies for patients at risk.

详细描述

One hundred and thiry-five patients with major depression diagnosed based on DSM-IV TR criteria between the ages of 21 and 65 (males, females and minorities) will be recruited. Forty-five patients with high inflammation as defined by a CRP >3 mg/L will be enrolled along with 45 depressed patients with medium inflammation (CRP=1-3mg/L) and 45 depressed patients with low inflammation (CRP<1mg/L) will complete a 2 night inpatient stay in Emory University Hospital's research unit, the Atlanta Clinical and Translational Science Institute (ACTSI). Participants will undergo psychiatric and neurocognitive assessments, sleep studies and blood and cerebral spinal fluid (CSF) sampling.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Cross Sectional

入排标准

年龄范围
21 Years 至 65 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • age 21-65 years including males, females and minorities
  • diagnosis of DSM-IV major depression or Bipolar I or II with current episode of depression
  • HDRS-17 > 20 and HDRS-24 > 24
  • negative pregnancy test for women of childbearing potential
  • not breast feeding
  • stable on current dose of psychotropic medication or free from all psychotropic medications for 4 weeks prior to EUH CIN admission (8 weeks for fluoxetine)
  • no suicide attempt within six months of screening

排除标准

  • evidence of untreated or poorly controlled endocrine, cardiovascular, pulmonary, hematological, renal, or neurological disease
  • history of CNS trauma or active seizure disorder requiring medication unless otherwise approved by principle investigator
  • autoimmune or inflammatory disorder of any kind
  • chronic infection (e.g. hepatitis B or C or HIV)
  • chronic use of agents known to affect the immune system including glucocorticoid therapy within the past 1 year, methotrexate within the past 1 year, chemotherapy of any kind (past or present), immunotherapy of any kind (past or present), aspirin or non-steroidal anti-inflammatory drugs (NSAIDs) (within the past 2 weeks) and statins (within the past 1 month) unless otherwise approved by principle investigator
  • hemoglobinopathies (e.g. thalassemia)
  • a positive pregnancy test
  • organ transplants
  • cancer of any type
  • a score of <28 on the Mini Mental Status Exam (MMSE)unless otherwise approved by principle investigator
  • meets criteria for schizophrenia (Given overlap of generalized anxiety disorder (GAD) with major depression, GAD will not be exclusionary)
  • current eating disorders
  • active abuse of alcohol or illicit/prescription drugs within the past year unless otherwise approved by principle investigator.
  • MGH-S >3 unless otherwise approved by principle investigator
  • BMI >40 unless otherwise approved by the principle investigator
  • active suicidal intent or plan and a score >2 on the HDRS suicide item (item #3).
  • any other condition which in the opinion of the investigator would make the patient unsuitable for enrollment, or could interfere with participating in or completing the protocol

结局指标

主要结局

We are using clinician administered and self report psychiatric measurements to compare relevant symptom domains in patients with major depression and increased inflammation versus patients with major depression without increased inflammation.

时间窗: Inpatient visit

Behavior: Hamilton Depression Rating Scale (HAM-D); Inventory of Depressive Symptoms-Self Report (IDS-SR); Salpetriere Retardation Rating Scale (SRRS); Snaith-Hamilton Pleasure Scale (SHAPS); Multidimensional Fatigue Inventory (MFI); Neuropsychology: Finger tapping task; Reaction Time Task (CANTAB); Trial Making Test, Part A; Digit Symbol Test; Stocking of Cambridge

次要结局

  • We are measuring immune markers for the identification of relevant immunologic patterns of activation in patients with major depression and increased inflammation versus patients with major depression without increased inflammation.(Inpatient visit; Day #2)

研究者

申办方类型
Other
责任方
Principal Investigator
主要研究者

Andrew H Miller

Professor, Psychiatry and Behavioral Sciences

Emory University

研究点 (1)

Loading locations...

相似试验